|

Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response.

RECRUITINGSponsored by Aalborg University Hospital
Actively Recruiting
SponsorAalborg University Hospital
Started2020-08-01
Est. completion2025-12-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04731831

Summary

The aim of the study is to explore whether the influence of gender, tobacco smoking and obesity on treatment response in tumor necrosis factor inhibitors (TNFIs) can be explained by high degree of inflammation, human leucocyte antigen (HLA) type, autoantibodies, TNF and TNFI concentration and presence of ADA.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients \> 18 years
* Diagnosed with RA, PsA or AS.
* Starting treatment with infliximab or adalimumab.
* Co- treatment with csDMARD or glucocorticoid is acceptable.
* No new bDMARD is initiated at the time of sampling.

Exclusion Criteria:

\-

Conditions5

ArthritisArthritis, PsoriaticArthritis, RheumatoidCancerSpondylitis, Ankylosing

Browse More Trials

Cancer trialsArthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.